Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.

“It’s our pleasure to welcome Matt to the Apollomics team. We expect his financial strategy and business development expertise from working with development and commercial stage public companies to be a critical asset as we execute our clinical, regulatory and commercialization plans,” said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. “His appointment comes at a time of promising opportunity and growth for the company. We look forward to his contributions as we continue to execute on our vision of bringing vebreltinib and our other pipeline candidates through clinical trials and towards regulatory approval.”

Dr. Plunkett added, “I am excited to join Apollomics at such an important point in the Company’s growth. The data for vebreltinib in various c-Met driven malignancies is compelling, and I look forward to working with the Apollomics leadership team to advance this drug candidate through development and help bring it to patients who could benefit from its differentiated activity and profile.”

Dr. Plunkett brings to Apollomics over 25 years of diverse strategic and financial experience within the biopharmaceutical sector, most recently as Chief Financial Officer at Aeovian Pharmaceuticals. Prior to Aeovian, he was Chief Financial Officer at Imago Biosciences (acquired by Merck), where he led the efforts for the company’s $155 million Nasdaq initial public offering (IPO). He was previously Chief Financial Officer at Nkarta Therapeutics, where he led the efforts for its $290 million Nasdaq IPO. He has held positions including Chief Business Officer at CTI BioPharma (acquired by SOBI), a commercial stage hematology-oncology biopharmaceutical company, where he led a variety of financing and corporate development transactions. Earlier in his career, Dr. Plunkett held a variety of positions at CIBC World Markets and its U.S. successor Oppenheimer & Co., including Managing Director, Head of West Coast Biotechnology. Dr. Plunkett received his B.S. in chemistry from Harvey Mudd College and a Ph.D. in organic chemistry from the University of California, Berkeley.